Imperial Valley News Center
Governor Newsom Announces Appointments
- Details
- Written by IVN
Sacramento, California - Governor Gavin Newsom today announced the following appointments:
Experimental respiratory syncytial virus vaccine prompts antibody surge
- Details
- Written by Anne A. Oplinger
Washington, DC - A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in the very young and the old, has shown early promise in a Phase 1 clinical trial. The candidate, DS-Cav1, was engineered and developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, who were guided by their atomic-level understanding of the shape of an RSV protein. An interim analysis of study data showed that one dose of the investigational vaccine prompted large increases in RSV-neutralizing antibodies that were sustained for several months. The findings are reported in Science.
Clinical trial to evaluate experimental treatment in people allergic to multiple foods
- Details
- Written by Judith Lavelle
Washington, DC - Though food allergy affects more than 4.8 million children in the United States, no approved preventative treatments currently exist. While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today. The study is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health; Genentech, a member of the Roche Group; and Novartis Pharmaceuticals Corporation.
Psoriasis therapy linked to reduced coronary inflammation in patients with the skin condition
- Details
- Written by National Heart, Lung, and Blood Institute
Washington, DC - Researchers have found that anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat attenuation index (FAI), that was able to measure the effect of the therapy in reducing the inflammation.
President Trump at Signing of a U.S.-EU Trade Agreement
- Details
- Written by IVN
Washington, DC - President Trump at Signing of a U.S.-EU Trade Agreement:
Bill Announcements
- Details
- Written by White House
Washington, DC - Today, the President signed into law:
Page 641 of 3785